FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313500534> ?p ?o ?g. }

• W4313500534 abstract "Abstract Background Treatment management after repeated failure of antiretroviral therapy (ART) is difficult due to resistance and adherence challenges. For people who have failed non-nucleoside reverse transcriptase inhibitor-(NNRTI-) and protease inhibitor-(PI-) based regimens with no or limited resistance, remaining on PI-based ART is an option. Using data from an ART strategy trial (A5288) in low/middle-income countries which included this option, we explored whether predictors can be identified distinguishing those who experienced further virologic failure from those who achieved and maintained virologic suppression. Methods A5288 enrolled people with confirmed HIV-1 RNA ≥ 1000 copies/mL after ≥ 24 weeks of PI-based ART and prior failure on NNRTI-based ART. This analysis focused on the 278 participants with no resistance to the PI being taken and no or limited nucleoside reverse transcriptase inhibitor (NRTI) resistance, who continued their PI with flexibility to change NRTIs. Proportional hazards models were used to evaluate predictors of virologic failure during follow-up (VF: confirmed HIV-1 RNA ≥ 1000 copies/mL at ≥ 24 weeks of follow-up). Results 56% of participants were female. At study entry, median age was 40 years, time on ART 7.8 years, CD4 count 169 cells/mm 3 , HIV-1 RNA 20,444 copies/mL; and 37% had NRTI resistance. The estimated proportion experiencing VF increased from 39% at week 24 to 60% at week 96. In multivariable analysis, significant predictors at study entry of VF were higher HIV-1 RNA (adjusted hazard ratio: 2.20 for ≥ 10,000 versus < 10,000 copies/mL), lower age (1.96 for < 30 versus ≥ 30 years), NRTI resistance (1.74 for present versus absent), lower CD4 count (1.73 for < 200 versus ≥ 200 cells/mm 3 ), and shorter ART duration (1.62 for < 10 versus ≥ 10 years). There was a strong trend in proportion with VF at week 96 with the number of these five risk factors that a participant had, varying from 8% for zero, to 31%, 40%, 73%, and 100% for one, two, three, and four/five. Only 13% of participants developed new NRTI or PI resistance mutations. Conclusion A simple count of five predictors might have value for identifying risk of continued VF. Novel antiretroviral and adherence support interventions are needed to improve virologic outcomes for higher risk individuals." @default.
• W4313500534 created "2023-01-06" @default.
• W4313500534 creator A5014418781 @default.
• W4313500534 creator A5024029270 @default.
• W4313500534 creator A5024931884 @default.
• W4313500534 creator A5025984594 @default.
• W4313500534 creator A5035635991 @default.
• W4313500534 creator A5038307269 @default.
• W4313500534 creator A5053042121 @default.
• W4313500534 creator A5056662537 @default.
• W4313500534 creator A5073643745 @default.
• W4313500534 creator A5088952559 @default.
• W4313500534 creator A5089045105 @default.
• W4313500534 creator A5090348690 @default.
• W4313500534 date "2023-01-05" @default.
• W4313500534 modified "2023-10-15" @default.
• W4313500534 title "Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance" @default.
• W4313500534 cites W2044731059 @default.
• W4313500534 cites W2095435063 @default.
• W4313500534 cites W2136708878 @default.
• W4313500534 cites W2154164013 @default.
• W4313500534 cites W2412211511 @default.
• W4313500534 cites W2530548126 @default.
• W4313500534 cites W2782561404 @default.
• W4313500534 cites W2887019425 @default.
• W4313500534 cites W2893564173 @default.
• W4313500534 cites W2896894134 @default.
• W4313500534 cites W2902199290 @default.
• W4313500534 cites W2943519321 @default.
• W4313500534 cites W2964910252 @default.
• W4313500534 cites W2966305835 @default.
• W4313500534 cites W2985718649 @default.
• W4313500534 cites W3006654921 @default.
• W4313500534 doi "https://doi.org/10.1186/s12981-022-00494-9" @default.
• W4313500534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36604746" @default.
• W4313500534 hasPublicationYear "2023" @default.
• W4313500534 type Work @default.
• W4313500534 citedByCount "0" @default.
• W4313500534 crossrefType "journal-article" @default.
• W4313500534 hasAuthorship W4313500534A5014418781 @default.
• W4313500534 hasAuthorship W4313500534A5024029270 @default.
• W4313500534 hasAuthorship W4313500534A5024931884 @default.
• W4313500534 hasAuthorship W4313500534A5025984594 @default.
• W4313500534 hasAuthorship W4313500534A5035635991 @default.
• W4313500534 hasAuthorship W4313500534A5038307269 @default.
• W4313500534 hasAuthorship W4313500534A5053042121 @default.
• W4313500534 hasAuthorship W4313500534A5056662537 @default.
• W4313500534 hasAuthorship W4313500534A5073643745 @default.
• W4313500534 hasAuthorship W4313500534A5088952559 @default.
• W4313500534 hasAuthorship W4313500534A5089045105 @default.
• W4313500534 hasAuthorship W4313500534A5090348690 @default.
• W4313500534 hasBestOaLocation W43135005341 @default.
• W4313500534 hasConcept C114851261 @default.
• W4313500534 hasConcept C126322002 @default.
• W4313500534 hasConcept C142462285 @default.
• W4313500534 hasConcept C159047783 @default.
• W4313500534 hasConcept C203014093 @default.
• W4313500534 hasConcept C207103383 @default.
• W4313500534 hasConcept C2777351918 @default.
• W4313500534 hasConcept C2781143361 @default.
• W4313500534 hasConcept C2781413609 @default.
• W4313500534 hasConcept C2909970146 @default.
• W4313500534 hasConcept C2993143319 @default.
• W4313500534 hasConcept C3013748606 @default.
• W4313500534 hasConcept C44249647 @default.
• W4313500534 hasConcept C71924100 @default.
• W4313500534 hasConcept C86803240 @default.
• W4313500534 hasConcept C89423630 @default.
• W4313500534 hasConceptScore W4313500534C114851261 @default.
• W4313500534 hasConceptScore W4313500534C126322002 @default.
• W4313500534 hasConceptScore W4313500534C142462285 @default.
• W4313500534 hasConceptScore W4313500534C159047783 @default.
• W4313500534 hasConceptScore W4313500534C203014093 @default.
• W4313500534 hasConceptScore W4313500534C207103383 @default.
• W4313500534 hasConceptScore W4313500534C2777351918 @default.
• W4313500534 hasConceptScore W4313500534C2781143361 @default.
• W4313500534 hasConceptScore W4313500534C2781413609 @default.
• W4313500534 hasConceptScore W4313500534C2909970146 @default.
• W4313500534 hasConceptScore W4313500534C2993143319 @default.
• W4313500534 hasConceptScore W4313500534C3013748606 @default.
• W4313500534 hasConceptScore W4313500534C44249647 @default.
• W4313500534 hasConceptScore W4313500534C71924100 @default.
• W4313500534 hasConceptScore W4313500534C86803240 @default.
• W4313500534 hasConceptScore W4313500534C89423630 @default.
• W4313500534 hasFunder F4320332161 @default.
• W4313500534 hasIssue "1" @default.
• W4313500534 hasLocation W43135005341 @default.
• W4313500534 hasLocation W43135005342 @default.
• W4313500534 hasLocation W43135005343 @default.
• W4313500534 hasOpenAccess W4313500534 @default.
• W4313500534 hasPrimaryLocation W43135005341 @default.
• W4313500534 hasRelatedWork W2074810364 @default.
• W4313500534 hasRelatedWork W2079342860 @default.
• W4313500534 hasRelatedWork W2107879921 @default.
• W4313500534 hasRelatedWork W2147933179 @default.
• W4313500534 hasRelatedWork W216481071 @default.
• W4313500534 hasRelatedWork W2169008341 @default.
• W4313500534 hasRelatedWork W2183166450 @default.
• W4313500534 hasRelatedWork W2503404095 @default.
• W4313500534 hasRelatedWork W4231069645 @default.

• next